#USA #New York #Class Action #Gross Law Firm #Unicycive

Unicycive Therapeutics Shareholders Take Action

In a recent announcement, The Gross Law Firm has reached out to shareholders of Unicycive Therapeutics, Inc., a company listed on NASDAQ under the ticker UNCY. This notice aims to inform and encourage those who suffered financial losses due to the company’s allegedly misleading statements to join a class action lawsuit.

What Happened?

The class action pertains specifically to shareholders who purchased UNCY shares during a specified class period, from March 29, 2024, to June 27, 2025. During this timeframe, the complaint states that the defendants provided materially false information about Unicycive's manufacturing compliance and regulatory readiness concerning its flagship drug application, oxylanthanum carbonate. This overstated the company’s readiness to satisfy the FDA’s compliance standards, leading to inflated stock prices that did not reflect the true value of the company.

Allegations Against Unicycive Therapeutics

Shareholders are urged to note the specific allegations:
1. Manufacturing Compliance Overstatement: The complaint asserts that Unicycive's claims on meeting FDA manufacturing regulations were exaggerated, suggesting a significant gap between reality and the company’s public statements.
2. Regulatory Prospects Overstatement: The lawsuit also highlights that the regulatory prospects of the oxylanthanum carbonate new drug application were overstated, thus misleading investors about the drug’s potential success.
3. Material Misleading Information: Overall, the public statements made by the defendants are claimed to be materially false and misleading during the relevant times.

Importance of Acting Quickly

Shareholders are encouraged to act promptly and not miss the October 14, 2025, deadline to register for the class action. By participating, shareholders can not only secure their rights but also be kept updated on the case’s developments through a dedicated portfolio monitoring system.

It is important to note that appointment as a lead plaintiff is not required to be part of the recovery process. The Gross Law Firm affirms that there are no costs or obligations associated with joining the lawsuit.

Why Choose Gross Law Firm?

The Gross Law Firm is known as a national leader in class action cases, focusing on protecting investors who have been victimized by fraudulent practices. Their mission centers around holding corporations accountable for misleading actions, ensuring they engage in ethical business practices, and defending the rights of the individuals who invest in them. Their track record in recovering losses for investors speaks volumes about their commitment to justice in the corporate environment.

Next Steps for Shareholders

Shareholders who believe they fall within the designated class period should take immediate action. To begin the registration process, they can follow the link provided by The Gross Law Firm, which allows them to submit necessary information securely. This step is crucial in ensuring participatory rights as the case progresses.

For any questions, potential plaintiffs can reach out directly to the firm via their contact information available on their website. With their vast experience and a dedicated legal team, The Gross Law Firm stands ready to assist affected investors in navigating the complexities of the legal process.

In conclusion, this class action presents an opportunity for Unicycive Therapeutics patients and shareholders to reclaim their losses. Timeliness in action will be a key factor in achieving recovery for those affected by this situation. With ongoing legal support from The Gross Law Firm, investors can have a sense of security as they approach this troubling issue.